Tuesday, January 11, 2011

Why Forbes’ Glaxo Story Was Totally Naive - Robert Langreth - Forbes

As I said in the story, ultimately, everything depends on whether Glaxo’s labs, and those of its partners, can produce important new drugs and sell them in new markets.  If it can’t, Witty will inevitably be forced to do the big deals he says he wants to avoid.

Posted via email from Jack's posterous

No comments: